The largest community of pharma leaders

Top 10 Pharmaceutical Companies 2017: Anti-Virals

Widespread infections caused by viruses are commonly known as viral diseases. Common types of viral diseases include cold, influenza, chickenpox, HIV/AIDS, viral hepatitis, HPV, viral meningitis, herpes, etc. These diseases are often contagious. When a virus enters the body and starts to multiply, they can spread from one person to another. Some of these viral diseases can be life-threatening, causing complications like pneumonia and diarrhea.


Viruses can spread from one person to another in different ways. For instance, air, food, or water contaminated with virus, or having sexual contact with an infected person can cause viral disease. In some cases, virus hosts, like mosquitoes or mouse can transmit the disease.

People of all ages can be affected by a viral disease. However, the very young and very old, and also those with chronic disease or a compromised or suppressed immune system are at greater risk of complications from these diseases. Centers for Disease Control and Prevention reports that between 71% and 85% of seasonal flu-related deaths occur in people 65 years and older each year, mainly because with age, human immune defenses become weaker. In the U.S., 57,062 persons died in 2015 due to influenza and pneumonia.

Market of Anti-Virals

In 2016, global ant-viral drugs sale reached $58.5bn, with the worldwide market share of 6.0%. Gilead Sciences dominated this market, with its global share of 57.1% in that year. The company earned $27.7bn in 2016 through selling anti-virals like Bictegravir/F/TAF, Descovy, and Genvoya.

GlaxoSmithKline is also maintaining its leading position due to the immense popularity of its HIV Integrase Inhibitor, which earned $2.4bn in 2016. The company also earned $1.3bn globally through the sales of another HIV Integrase Inhibitor called Tivicay. Another dominant player in this anti-viral market is Merck & Co, which earned $2.1bn in 2016, with 4.3% of market share.





 Luca Dezzani is a Novartis employee. All the views, analysis, and perspectives are fully independent and belongs to the author only. They do not represent the views or opinions of Novartis or any other company or organization. IgeaHub is a pharmaceutical blog created and curated by Luca Dezzani.  IgeaHub does not receive any funding or support from Novartis or any other pharmaceutical company. 

Recent Articles